biostudies-literatureUnknownDoherty JAbbott LaboratoriesUniversity College Dublin,INITIative Newman FellowshipAbbott DiagnosticsDiagnostic DivisionEvidence suggests patients with inflammatory bowel disease (IBD) receiving TNF-antagonists have attenuated response to vaccination against COVID-19. We sought to determine the impact of IBD and various medications for treatment of IBD on antibody responses to vaccination against COVID-19. Patients with IBD (n=270) and healthy controls (HC, n=116) were recruited prospectively and quantitative antibody responses assessed following COVID-19 vaccination. The impact of IBD and medications for treatment of IBD on vaccine response rates was investigated. 100% of HC seroconverted post-complete vaccination with two vaccine doses. 2% of patients with IBD failed to seroconvert. Median anti-spike protein (SP) immunoglobulin (Ig)G levels post-complete vaccination in our IBD cohort was significantly lowJournal of Crohn's & colitisjjac029https://www.ebi.ac.uk/biostudies/studies/S-EPMC8903431biostudies-literatureReduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON).PMC8903431Sheridan JDoran PO Morain NMc Dermott EStack RInzitiari RDoherty GAMulcahy HRyan EJDaghfal DGirod PCullen GDoherty JHorgan GTosetto MO Morain CBuckley MfalseReduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON).Evidence suggests patients with inflammatory bowel disease (IBD) receiving TNF-antagonists have attenuated response to vaccination against COVID-19. We sought to determine the impact of IBD and various medications for treatment of IBD on antibody responses to vaccination against COVID-19. Patients with IBD (n=270) and healthy controls (HC, n=116) were recruited prospectively and quantitative antibody responses assessed following COVID-19 vaccination. The impact of IBD and medications for treatment of IBD on vaccine response rates was investigated. 100% of HC seroconverted post-complete vaccination with two vaccine doses. 2% of patients with IBD failed to seroconvert. Median anti-spike protein (SP) immunoglobulin (Ig)G levels post-complete vaccination in our IBD cohort was significantly low2022-01-01T00:00:00Z2022 Feb2025-05-29T22:10:46.508Z2025-05-29T22:10:46.508ZS-EPMC89034313517677010.1093/ecco-jcc/jjac029